BOSTON--(BUSINESS WIRE)--CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, today announced a $13.5 million seed extension financing and the appointment of Sameer Rohatgi of LYFE Capital to their Board of Directors.

波士顿--（商业新闻短讯）--细胞电子学公司，一家基于半导体的细胞生物学发现平台的先驱，今天宣布了1350万美元的种子推广融资，并任命LYFE Capital的Sameer Rohatgi为董事会成员。

The Series Seed 2 round was led by new investor, LYFE Capital, and existing investor Anzu Partners. New investors including Legend Star, RIT Venture Fund (Rochester Institute of Technology), and Draper Associates also joined the round, with continued support from BoxOne Ventures and other minority financial supporters.

系列种子2轮由新投资者LYFE Capital和现有投资者Anzu Partners牵头。包括Legend Star、RIT风险基金（罗切斯特理工学院）和Draper Associates在内的新投资者也加入了这轮投资，BoxOne Ventures和其他少数族裔金融支持者继续提供支持。

The additional capital enables CytoTronics to build off a successful early access program and accelerate market entry of their semiconductor-to-live-cell interface for cell biology applications, Pixel™..

额外的资金使CytoTronics能够建立一个成功的早期接入计划，并加速其用于细胞生物学应用的半导体到活细胞界面Pixel™的市场进入。。

“The field has been seeking a live cell analysis platform that provides exquisite resolution and outputs numerous data points to conduct multiple measurements. We’re impressed with the CytoTronics team and excited to support their commercial launch of Pixel and future platforms,” said Sameer Rohatgi, Partner at LYFE Capital.

LYFE Capital合伙人Sameer Rohatgi表示：“该领域一直在寻求一种活细胞分析平台，该平台可提供精确的分辨率，并输出大量数据点以进行多次测量。我们对CytoTronics团队印象深刻，并很高兴能支持其Pixel和future平台的商业推出。”。

Sameer brings 20+ years of industry experience to the CytoTronics Board of Directors, spanning life science tools, diagnostics and implantable medical devices. Prior to joining LYFE Capital, he worked at Illumina as Head of International Corporate and Business Development. At Agilent Technologies, Sameer was Director of Genomics Marketing for the Genomics business unit, and held leadership roles in business development at both Agilent Technologies and Incyte Genomics..

Sameer为CytoTronics董事会带来了20多年的行业经验，涵盖生命科学工具、诊断和植入式医疗设备。在加入LYFE Capital之前，他曾在Illumina担任国际公司和业务发展负责人。在安捷伦科技公司，Sameer是基因组学业务部门的基因组学营销总监，并在安捷伦科技公司和Incyte Genomics的业务发展中担任领导角色。。

CytoTronics’ Pixel assesses live cell function at single-cell resolution, offering scientists simultaneous, multi-modal monitoring of cell viability, morphology, electrophysiology, and more while generating electrical images with single-cell spatial resolution. Pixel received the 2024 New Product Award by the Society for Laboratory Automation and Screening in February, and a R&D 100 award from Research & Development World in August.

CytoTronics的像素以单细胞分辨率评估活细胞功能，为科学家提供细胞活力，形态，电生理等的同时多模式监测，同时生成具有单细胞空间分辨率的电子图像。Pixel于2月获得了实验室自动化和筛选学会颁发的2024年新产品奖，并于8月获得了研发世界颁发的研发100奖。

Early access for the company’s second system, Pixel Octo, kicked off in July and is poised to break scalability barriers for monitoring live cell function in high-throughput cell biology discovery applications..

该公司第二个系统Pixel Octo的早期访问于7月启动，有望打破高通量细胞生物学发现应用中监测活细胞功能的可扩展性障碍。。

“In just six short months, Pixel has received two prestigious awards and an overwhelmingly positive response from our global collaborations with early adopters in both industry and academia. Continued support from our existing investors, enthusiasm from our new investor partners, and customer excitement around Pixel really strenghthens momentum as CytoTronics enters this new stage of growth,” said Jeffrey Abbott, Ph.D., Co-Founder and CEO of CytoTronics.

CytoTronics联合创始人兼首席执行官杰弗里·阿博特（JeffreyAbbott）博士表示：“在短短的六个月内，Pixel获得了两项久负盛名的奖项，我们与业界和学术界早期采用者的全球合作获得了压倒性的积极回应。现有投资者的持续支持、新投资者合作伙伴的热情以及围绕Pixel的客户兴奋，确实增强了CytoTronics进入这一新增长阶段的势头。”。

“This funding round will support expansion of our commercial and field teams, manufacturing, and production as we gear up for our first product shipments in 2025.”.

“随着我们为2025年的第一批产品发货做好准备，这轮融资将支持我们的商业和现场团队、制造和生产的扩张。”。

Anzu Partners led the original Series Seed 1 funding in 2021, powering CytoTronics’s spin out from Harvard University. “As an early investor in CytoTronics, we are thrilled with the progress the team has made over the past year with the successful launch of Pixel Primo and Pixel Octo,” said Jenna Abelli, Principal at Anzu Partners and Member of CytoTronics Board of Directors.

Anzu Partners于2021年领导了最初的系列种子1基金，为哈佛大学的CytoTronics螺旋输出提供了动力。Anzu Partners负责人兼CytoTronics董事会成员Jenna Abelli表示：“作为CytoTronics的早期投资者，我们对团队在过去一年中成功推出Pixel Primo和Pixel Octo所取得的进展感到兴奋。”。

“CytoTronics’ technology has the potential to advance various realms of cell biology and discovery, catalyzing broader scientific progress that could improve lives. We are excited to continue our support as an investor to further this mission.”.

“CytoTronics的技术有可能推进细胞生物学和发现的各个领域，催化更广泛的科学进步，从而改善生活。我们很高兴作为投资者继续支持这项使命。”。

To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com.

要了解有关Pixel的更多信息或参加早期访问计划，请访问www.cytotronics.com。

About CytoTronics

关于CytoTronics

At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications.

在CytoTronics，我们正在利用基于半导体的高通量平台改变细胞生物学发现。我们的像素系统为所有细胞类型提供单细胞分辨率的活细胞见解。通过将半导体与传统微孔板无缝集成，Pixel解锁了多模式电，电化学和电生理功能，为细胞生物学研究，药物开发和制药制造应用提供了前所未有的数据收集和放大范围。

Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at cytotronics.com or follow us on LinkedIn..

我们于2021年从哈佛大学分拆成立，总部位于马萨诸塞州波士顿。请访问cytotronics.com了解更多信息，或在LinkedIn上关注我们。。